Analysed DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) News Sources
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26
23-03-2026
yahoo.com
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
18-03-2026
yahoo.com
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development
10-03-2026
yahoo.com
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
02-02-2026
yahoo.com
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
12-01-2026
yahoo.com
DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15
30-12-2025
yahoo.com
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron
22-12-2025
yahoo.com
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
22-12-2025
yahoo.com
What is the current price of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)?
The current price of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) is $1.99.
DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) since the previous trading day is $0.01.
DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) since the previous trading day is 0.5051%.
What is the most recent average sentiment score for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)?
The most recent average sentiment score for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)?
The most recent sentiment for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) is .
SEC-8K** Filing Available For DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.